Literature DB >> 19052182

Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapy.

Rosendo Jardi1, Francisco Rodriguez-Frias, David Tabernero, Maria Homs, Melanie Schaper, Rafael Esteban, Maria Buti.   

Abstract

A line probe assay (INNO-LiPA DR, version 3) for the detection of hepatitis B virus mutations that confer resistance to entecavir therapy was evaluated. The INNO-LiPA DR assay is a highly sensitive assay that is easily applicable for the detection and monitoring of entecavir resistance-conferring mutations and is more sensitive than sequencing for the detection of mixed sequences.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19052182      PMCID： PMC2643676          DOI： 10.1128/JCM.01678-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  13 in total

1.  Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).

Authors:  Carla Osiowy; Jean-Pierre Villeneuve; E Jenny Heathcote; Elizabeth Giles; Jamie Borlang
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

Review 2.  Antiviral therapy of chronic hepatitis B.

Authors:  Fabien Zoulim
Journal:  Antiviral Res       Date:  2006-04-25       Impact factor: 5.970

3.  Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.

Authors:  Stéphanie Villet; Aurélie Ollivet; Christian Pichoud; Luc Barraud; Jean-Pierre Villeneuve; Christian Trépo; Fabien Zoulim
Journal:  J Hepatol       Date:  2006-12-18       Impact factor: 25.083

4.  Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.

Authors:  Daniel J Tenney; Ronald E Rose; Carl J Baldick; Steven M Levine; Kevin A Pokornowski; Ann W Walsh; Jie Fang; Cheng-Fang Yu; Sharon Zhang; Charles E Mazzucco; Betsy Eggers; Mayla Hsu; Mary Jane Plym; Patricia Poundstone; Joanna Yang; Richard J Colonno
Journal:  Antimicrob Agents Chemother       Date:  2006-12-18       Impact factor: 5.191

5.  Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

Authors:  K Das; X Xiong; H Yang; C E Westland; C S Gibbs; S G Sarafianos; E Arnold
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

6.  Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.

Authors:  R J Colonno; E V Genovesi; I Medina; L Lamb; S K Durham; M L Huang; L Corey; M Littlejohn; S Locarnini; B C Tennant; B Rose; J M Clark
Journal:  J Infect Dis       Date:  2001-10-29       Impact factor: 5.226

7.  Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.

Authors:  D J Tenney; S M Levine; R E Rose; A W Walsh; S P Weinheimer; L Discotto; M Plym; K Pokornowski; C F Yu; P Angus; A Ayres; A Bartholomeusz; W Sievert; G Thompson; N Warner; S Locarnini; R J Colonno
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

8.  Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues.

Authors:  Francisco Rodriguez-Frias; Rosendo Jardi; Melanie Schaper; Montserrat Gimferrer; Ioannis Elefsiniotis; David Tabernero; Rafael Esteban; Maria Buti
Journal:  J Med Virol       Date:  2007-11       Impact factor: 2.327

9.  Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy.

Authors:  Rosendo Jardi; Francisco Rodriguez-Frias; Melanie Schaper; Elena Giggi; David Tabernero; Maria Homs; Rafael Esteban; Maria Buti
Journal:  J Hepatol       Date:  2008-05-06       Impact factor: 25.083

10.  Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants.

Authors:  Munira Hussain; Chi-Jen Chu; Erwin Sablon; Anna S F Lok
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948
View more
  2 in total

Review 1.  Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  Molecular diagnosis of entecavir resistance.

Authors:  Murat Sayan
Journal:  Hepat Mon       Date:  2010-03-01       Impact factor: 0.660
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.